Curis Strengthens Management Team.Business Editors/Health/Medical Writers CAMBRIDGE, Mass.Curis--(BUSINESS WIRE)--Nov. 25, 2003 Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CRIS) today announced significant strengthening of its management team. Commenting on the changes, Daniel Passeri, Curis' President and Chief Executive Officer, said, "Curis has made remarkable progress in 2003 by focusing on fiscal discipline and corporate collaborations. Today's appointments are aimed at bringing Curis to the next level in its development as a diversified product-focused company." First, Michael P. Gray, who most recently held the position of Senior Director of Finance and Controller, will assume the position of Vice President of Finance and Chief Financial Officer. Mr. Gray has been with Curis since its inception in August of 2000. Mr. Gray will further share responsibility for investor relations Investor relations The process by which the corporation communicates with its investors. with Dr. Marc Charette, Vice President of Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. . Also, Dr. Christopher Dr. John R. Christopher, known popularly as "Dr. Christopher" was one of very few nationally prominent doctors of herbal medicine of the middle third of the 20th century, a "dark ages" of herbalism and was responsible for the herbal renaissance of the 1960s. U. Missling, who presently serves as Vice President of Finance and Chief Financial Officer, will be appointed to the newly created position of Senior Vice President, Strategic Analysis and Planning. Dr. Missling will be responsible for strategic modeling of Curis resources and assets in the fields and markets for which its drug development technologies are targeted. Dan Passeri also remarked, "Both Christopher Missling and Mike Gray have played pivotal roles in the last year as we have implemented the new business model. Their combined financial experience and familiarity with Curis' technologies will be great assets as we continue with the transition." About Curis, Inc. Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease Kidney Disease Definition Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease. , neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). , cancer, and alopecia alopecia (ăl'əpē`shēə): see baldness. (hair loss). For more information, please visit the Curis web site at www.curis.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion